Fig. 1.
Regulation of YAP/TAZ during MASLD progression in patients and experimental animal models. YAP/TAZ activity during different stages of MASLD. YAP/TAZ expression or activity observed in patients (blue box) and mouse models to mimic human disease (green box) are shown. In physiological conditions, YAP expression is mostly restricted to cholangiocytes in both humans and mice (yellow box). APAP acetaminophen; CCA cholangiocarcinoma; CCl4 carbon tetrachloride; CDAHFD choline-deficient amino acid-defined high-fat diet; DEN diethylnitrosamine; FPC high-fructose high-palmitate and high-cholesterol diet; HCC hepatocellular carcinoma; HFD high-fat diet; LPS lipopolysaccharide; MCD methionine- and choline-deficient diet; MyrAKT O/E Hepatocytic overexpression of myristoylated AKT